文献速递精神分裂症与精神病性障碍

经颅直流电刺激治疗精神分裂症阴性症状的随机临床试验

Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2020-01-01

巴西圣保罗2家门诊开展的双盲STARTS随机临床试验纳入100例精神分裂症伴显著阴性症状患者,比较活性经颅直流电刺激(tDCS)与假刺激作为附加治疗的疗效与安全性。结果显示活性tDCS在改善PANSS阴性症状子量表评分上显著优于假刺激,且疗效在随访期持续,总体耐受良好。

要点

  • 活性tDCS组PANSS阴性症状评分改善显著优于假刺激组,差异为2.65(95%CI 1.51-3.79)。
  • 阴性症状应答率活性组40%(20/50)高于假刺激组4%(2/50)。
  • 除头皮灼烧感外,两组不良反应无差异,tDCS总体耐受良好。

核心结论

  • tDCS作为附加治疗可有效且安全地改善精神分裂症患者的阴性症状,疗效在随访期持续。

研究设计与样本

  • 双盲随机临床试验(STARTS),2014年9月至2018年3月在巴西圣保罗州2家门诊开展。
  • 纳入100例精神分裂症患者,阴性及阳性症状稳定,PANSS阴性症状子量表最低20分;20例(20.0%)为女性,平均(SD)年龄35.3(9.3)岁,95例(95.0%)完成试验。
  • 干预为5天内每日2次共10次tDCS或假刺激,阳极置于左前额叶皮层、阴极置于左颞顶交界区;主要结局为第6周PANSS阴性症状子量表评分变化,另随访6周。

主要发现

  • 意向性治疗分析中,活性tDCS组PANSS评分改善显著大于假刺激组,差异2.65(95%CI 1.51-3.79),需治疗人数3.18(95%CI 2.12-6.99),P<.001。
  • 阴性症状应答率(改善≥20%)活性组为20/50(40%),假刺激组为2/50(4%),P<.001。
  • 上述效应在随访期持续;tDCS耐受良好,除活性组头皮灼烧感43.8%对假刺激组14.3%(P=.003)外,两组不良反应无差异。

关键数值与推荐

  • 纳入标准:PANSS阴性症状子量表评分至少20分。
  • 主要结局:第6周PANSS阴性症状子量表评分变化。
  • 阴性症状应答定义:改善20%或以上。

临床怎么用

  • 对于精神分裂症伴显著阴性症状且症状稳定的门诊患者,可考虑在常规治疗基础上附加tDCS。
  • 治疗为5天内每日2次共10次,阳极置左前额叶皮层、阴极置左颞顶交界区,需注意头皮灼烧感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Negative symptoms represent a substantial burden in schizophrenia. Although preliminary studies have suggested that transcranial direct current stimulation (tDCS) is effective for some clusters of symptoms, the clinical benefits for negative symptoms are unclear. OBJECTIVE: To determine the efficacy and safety of tDCS vs sham as an add-on treatment for patients with schizophrenia and predominant negative symptoms. DESIGN, SETTING, AND PARTICIPANTS: The double-blind Schizophrenia Treatment With Electric Transcranial Stimulation (STARTS) randomized clinical trial was conducted from September 2014 to March 2018 in 2 outpatient clinics in the state of São Paulo, Brazil. Patients with schizophrenia with stable negative and positive symptoms and a minimum score of 20 points in the negative symptoms subscale of the Positive and Negative Syndrome Scale (PANSS) were included. INTERVENTIONS: Ten sessions of tDCS performed twice a day for 5 days or a sham procedure. The anode and the cathode were positioned over the left prefrontal cortex and the left temporoparietal junction, respectively. MAIN OUTCOMES AND MEASURES: Change in the PANSS negative symptoms subscale score at week 6 was the primary outcome. Patients were followed-up for an additional 6 weeks. RESULTS: Of the 100 included patients, 20 (20.0%) were female, and the mean (SD) age was 35.3 (9.3) years. A total of 95 patients (95.0%) finished the trial. In the intention-to-treat analysis, patients receiving active tDCS showed a significantly greater improvement in PANSS score compared with those receiving the sham procedure (difference, 2.65; 95% CI, 1.51-3.79; number needed to treat, 3.18; 95% CI, 2.12-6.99; P < .001). Response rates for negative symptoms (20% improvement or greater) were also higher in the active group (20 of 50 [40%]) vs the sham group (2 of 50 [4%]) (P < .001). These effects persisted at follow-up. Transcranial direct current stimulation was well tolerated, and adverse effects did not differ between groups, except for burning sensation over the scalp in the active group (43.8%) vs the sham group (14.3%) (P = .003). CONCLUSIONS AND RELEVANCE: Transcranial direct current stimulation was effective and safe in ameliorating negative symptoms in patients with schizophrenia. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02535676.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Valiengo LDCL, Goerigk S, Gordon PC, et al. Efficacy and Safety of Transcranial Direct Current Stimulation for Treating Negative Symptoms in Schizophrenia: A Randomized Clinical Trial. JAMA Psychiatry. 2020. PMID: 31617873. doi:10.1001/jamapsychiatry.2019.3199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。